The first combined vaccine against hepatitis A and B: an overview.

Hepatitis A and B infections are prevalent world-wide and are a significant cause of morbidity and mortality. A vaccine providing dual protection against hepatitis A and B is now available (Twinrix, SmithKline Beecham Biologicals). Six pivotal vaccine trials, involving 843 healthy adults, aged between 17 and 60 years and vaccinated following a 0, 1, 6 month schedule are discussed. At month 2 more than 99% of the vaccinees were seropositive for anti-HAV and 84% were protected against hepatitis B. The third dose induced a 12-fold increase in geometric mean titres (GMTs) to 5404 mIU/ml. One month after completion of the vaccination course nearly all vaccinees had protective titres against hepatitis B with a GMT of 4818 mIU/ml. Long term follow-up data until month 48 is available for two studies. At month 48 all 129 vaccinees sampled were still positive for anti-HAV antibodies and > 95% were still protected against hepatitis B. The combined hepatitis A and B vaccine Twinrix proves to be consistently safe, well tolerated and highly immunogenic and compares well with serological responses reached with monovalent vaccines. This combined hepatitis A and B vaccine offers more convenience, potentially better compliance and lower administration costs.
AuthorsS Thoelen, P Van Damme, A Leentvaar-Kuypers, G Leroux-Roels, M Bruguera, P C Frei, V Bakasenas, A Safary
JournalVaccine (Vaccine) Vol. 17 Issue 13-14 Pg. 1657-62 (Mar 26 1999) ISSN: 0264-410X [Print] ENGLAND
PMID10194819 (Publication Type: Journal Article)
Chemical References
  • Hepatitis A Vaccines
  • Hepatitis Antibodies
  • Hepatitis B Vaccines
  • Vaccines, Combined
  • Viral Hepatitis Vaccines
  • Adolescent
  • Adult
  • Clinical Trials as Topic
  • Female
  • Follow-Up Studies
  • Hepatitis A Vaccines
  • Hepatitis Antibodies (blood)
  • Hepatitis B Vaccines (immunology)
  • Humans
  • Male
  • Middle Aged
  • Vaccination
  • Vaccines, Combined (immunology)
  • Viral Hepatitis Vaccines (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: